Pulmonary Arterial Hypertension (PAH): Drug Development Pipeline Study, H1 2018

  • ID: 4487525
  • Report
  • Region: Global
  • 118 Pages
  • VPA Research
1 of 6
53 Active Drugs and 60+ Companies are Analyzed

FEATURED COMPANIES

  • Aadi Bioscience, Inc.
  • Biogen, Inc.
  • Galectin Therapeutics Inc
  • Lung Biotechnology PBC
  • Novartis International AG
  • Savara Inc
  • MORE

Pulmonary Arterial Hypertension (PAH) is a rare and catastrophic condition, with an estimated market value of over $4 billion. The chronic and rapidly progressing disease affects around 0.2 million to 0.3 million people globally.

It is characterized by enlargement of arterial walls within the small pulmonary arteries transporting high pressure blood between the heart and lungs, resulting in strain on the heart and thereby, restricted blood flow. Disease symptoms include breath shortage, chest pain and fainting episodes.

Endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, prostacyclin analogues and soluble guanylate cyclase (sGC) stimulators are the primary treatment options for PAH. However, as the underlying mechanism is yet unknown, the current therapies reduce the effect of PAH but do not impact the underlying cause.

The most comprehensive pipeline review “Pulmonary Arterial Hypertension (PAH)Drug Development Pipeline Study” provides in-depth analysis and update information on Pulmonary Arterial Hypertension (PAH) pipeline drugs. Current status of all the drugs in the Pulmonary Arterial Hypertension (PAH) pipeline is provided in the research work.

The report provides detailed analysis of Pulmonary Arterial Hypertension (PAH) pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Pulmonary Arterial Hypertension (PAH) report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Pulmonary Arterial Hypertension (PAH) industry.

Scope:

  • All latest industry developments and their impact on projects and companies
  • Complete overview of global Pulmonary Arterial Hypertension (PAH) therapy options and treatments
  • The pipeline study reviews drug details for Pulmonary Arterial Hypertension (PAH) by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
  • Mergers, Acquisitions, licensing, co-development and project acquisition news for Pulmonary Arterial Hypertension (PAH) market
  • Pulmonary Arterial Hypertension (PAH) drugs being developed in combination with other drugs are also detailed
  • Company wise drugs listed with their current status, partners and news updates

Products Mentioned:

  • ABI-009
  • acebilustat
  • Aironite
  • APT-102
  • AV-353
  • Bardoxolone Methyl
  • Beraprost 314d
  • Beraprost 314d and treprostinil
  • BIA 5-1058
  • BMP10
  • BMP9
  • C21
  • CAM 2043
  • CAP 1002
  • CXA-10
  • CXL-1036
  • Dimethyl Fumarate
  • Epoprostenol inhalation(flolan)
  • GM CT-01
  • GMA302
  • GR MD-02
  • GSK 2256098
  • GSK 2586881
  • INS1009
  • Intravenous L-citrulline
  • INV-240
  • KAR5585
  • LIQ861
  • LT-2004
  • Macitentan/tadalafil
  • MFC1040
  • MFC2040
  • oligonucleotide designed to inhibit miR-145 (microRNA-145)
  • PB1046
  • PK10453
  • PK10571
  • PT2567
  • QCC 374
  • R197
  • Ralinepag
  • RP5063
  • RT234 AOS DPI
  • SER100PH
  • Sotatercept
  • SPI-054
  • SUD-004
  • tacrolimus
  • Tiprelestat
  • tocilizumab
  • TR-422
  • Treprostinil PatchPump
  • treprostinil prodrug transdermal
  • Treprostinil Technosphere
  • Udenafil
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aadi Bioscience, Inc.
  • Biogen, Inc.
  • Galectin Therapeutics Inc
  • Lung Biotechnology PBC
  • Novartis International AG
  • Savara Inc
  • MORE

1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Disease Overview
2.2 pipeline Snapshot
2.3 pipeline Drugs by Phase
2.4 pipeline Drugs by Company
2.5 pipeline Drugs by Mechanism of Action

3 Pulmonary Arterial Hypertension- Company wise pipeline Analysis
3.1 AADI BIOSCIENCE, INC. pipeline, H1 2018
3.2 Acceleron Pharma Inc pipeline, H1 2018
3.3 ACTELION PHARMACEUTICALS pipeline, H1 2018
3.4 Aerogen Pharma Limited pipeline, H1 2018
3.5 APT Therapeutics, Inc. pipeline, H1 2018
3.6 Arena Pharmaceuticals Inc.pipeline, H1 2018
3.7 ASKLEPION PHARMACEUTICALS, LLC pipeline, H1 2018
3.8 AVEO PHARMACEUTICALS INC. pipeline, H1 2018
3.9 BIAL-PORTELA & CA. S.A pipeline, H1 2018
3.10 BIOGEN, INC. pipeline, H1 2018
3.11 BRISTOL-MYERS SQUIBB CO pipeline, H1 2018
3.12 Camurus AB pipeline, H1 2018
3.13 CAPRICOR THERAPEUTICS, INC pipeline, H1 2018
3.14 CELSION CORP pipeline, H1 2018
3.15 CELTAXSYS, INC. pipeline, H1 2018
3.16 CHUGAI PHARMACEUTICAL CO LTD pipeline, H1 2018
3.17 Complexa Inc pipeline, H1 2018
3.18 CORSAIR PHARMA, INC. pipeline, H1 2018
3.19 GALECTIN THERAPEUTICS INC pipeline, H1 2018
3.20 GLAXOSMITHKLINE PHARMACEUTICALS LTDpipeline, H1 2018
3.21 GMAX BIOPHARM BIOMEDICAL ENGINEERING CO., LTD.pipeline, H1 2018
3.22 INSMED, INC.pipeline, H1 2018
3.23 INVENT PHARMACEUTICALS, INC. pipeline, H1 2018
3.24 KAROS PHARMACEUTICALS, INC pipeline, H1 2018
3.25 LIQUIDIA TECHNOLOGIES INC pipeline, H1 2018
3.26 LTT BIO-PHARMA CO., LTD. pipeline, H1 2018
3.27 LUNG BIOTECHNOLOGY PBC pipeline, H1 2018
3.28 MANNKIND CORP pipeline, H1 2018
3.29 MaxCyte, Inc. pipeline, H1 2018
3.30 MEZZION PHARMA CO LTD pipeline, H1 2018
3.31 MIFCARE.CA pipeline, H1 2018
3.32 MORPHOGEN-IX LIMITED pipeline, H1 2018
3.33 NOVARTIS INTERNATIONAL AG pipeline, H1 2018
3.34 PELOTON THERAPEUTICS INC pipeline, H1 2018
3.35 PHASEBIO PHARMACEUTICALS, INC pipeline, H1 2018
3.36 PROTEO BIOTECH AG pipeline, H1 2018
3.37 PULMOKINE, INC pipeline, H1 2018
3.38 RADIKAL THERAPEUTICS INC pipeline, H1 2018
3.39 Reata Pharmaceuticals Inc pipeline, H1 2018
3.40 RESPIRA THERAPEUTICS, INC pipeline, H1 2018
3.41 Reviva Pharmaceuticals, Inc pipeline, H1 2018
3.42 SAVARA INC pipeline, H1 2018
3.43 Selten Pharma, LLC. pipeline, H1 2018
3.44 SERODUS ASA pipeline, H1 2018
3.45 STEADYMED THERAPEUTICS INC pipeline, H1 2018
3.46 SUDA LTD pipeline, H1 2018
3.47 Tritech Biopharmaceuticals Co Ltd pipeline, H1 2018
3.48 Vicore Pharma AB pipeline, H1 2018
3.49 Vivus Inc pipeline, H1 2018

4 Pulmonary Arterial Hypertension Drug Snapshots
4.1 SOTATERCEPT DRUG DETAILS
4.1.1 Snapshot
4.1.2 Drug Details
4.1.3 Mechanism of Action
4.1.4 Current Status
4.2 Epoprostenol inhalation (flolan) Drug Details
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.2.5 Trial details
4.3 Ralinepag Drug Details
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.3.5 Trial details
4.4 Beraprost 314d Drug Details
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.4.5 Trial details
4.5 LT-2004 Drug Details
4.5.1 Snapshot
4.5.2 Drug overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 Intravenous L-citrulline Drug Details
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 AV-353 Drug Details
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial details
4.8 BIA 5-1058 Drug Details
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial details
4.9 Dimethyl Fumarate Drug Details
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.9.5 Trial details
4.10 CXL-1036 Drug Details
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.11 CAM 2043 Drug Details
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.11.5 Trial Details
4.12 CAP 1002 Drug Details
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.12.5 Trial details
4.13 TheraSilence Drug Details
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.13.5 Trial Details
4.14 acebilustat Drug Details
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 tocilizumab Drug Details
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.15.5 Trial details
4.16 CXA-10 Drug Details
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.16.5 Trial details
4.17 GM CT-01 Drug Details
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.17.5 Trial Details
4.18 GR MD-02 Drug Details
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.18.5 Trial Details
4.19 GSK 2256098 Drug Details
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.19.5 Trial Details
4.20 GSK 2586881 Drug Details
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.20.5 Trial details
4.21 INS1009 Drug Details
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.21.5 Trial details
4.22 LIQ861 Drug Details
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.22.5 Trial Details
4.23 Treprostinil Technosphere Drug Details
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 Udenafil Drug Details
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.24.5 Trial details
4.25 eNOS-EPC Cells Drug Details
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.25.5 Trial Details
4.26 QCC 374 Drug Details
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.26.5 Trial details
4.27 PT2567 Drug Details
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.28 PB1046 Drug Details
4.28.1 Snapshot
4.28.2 Drug Overview
4.28.3 Mechanism of Action
4.28.4 Current Status
4.28.5 Trial Details
4.29 PK10571 Drug Details
4.29.1 Snapshot
4.29.2 Drug Overview
4.29.3 Mechanism of Action
4.29.4 Current Status
4.30 Bardoxolone Methyl Drug Details
4.30.1 Snapshot
4.30.2 Drug Overview
4.30.3 Mechanism of Action
4.30.4 Current Status
4.30.5 Trial Details
4.31 RT234 AOS DPI Drug Details
4.31.1 Snapshot
4.31.2 Drug Overview
4.31.3 Mechanism of Action
4.31.4 Current Status
4.32 RP5063 Drug Details
4.32.1 Snapshot
4.32.2 Drug Overview
4.32.3 Mechanism of Action
4.32.4 Current Status
4.32.5 Trial details
4.33 Aironite Drug Details
4.33.1 Snapshot
4.33.2 Drug Overview
4.33.3 Mechanism of Action
4.33.4 Current Status
4.33.5 Trial Details
4.34 SER100PH Drug Details
4.34.1 Snapshot
4.34.2 Drug Overview
4.34.3 Mechanism of Action
4.34.4 Current Status
4.35 Treprostinil Patch Pump Drug Details
4.35.1 Snapshot
4.35.2 Drug Overview
4.35.3 Mechanism of Action
4.35.4 Current Status
4.36 SUD-004 Drug Details
4.36.1 Snapshot
4.36.2 Drug Overview
4.36.3 Current Status
4.36.4 Mechanism of Action
4.37 treprostinil prodrug transdermal Drug Details
4.37.1 Snapshot
4.37.2 Drug Overview
4.37.3 Mechanism of Action
4.37.4 Current Status
4.38 C21 Drug Details
4.38.1 Snapshot
4.38.2 Drug Overview
4.38.3 Mechanism of Action
4.38.4 Current Status
4.38.5 Trial Details
4.39 Macitentan/tadalafil Drug Details
4.39.1 Snapshot
4.39.2 Drug Overview
4.39.3 Mechanism of Action
4.39.4 Current Status
4.39.5 Trial details
4.40 APT-102 Drug Details
4.40.1 Snapshot
4.40.2 Drug Overview
4.40.3 Mechanism of Action
4.40.4 Current Status
4.40.5 Trial Details
4.41 BMP10 Drug Details
4.41.1 Snapshot
4.41.2 Drug Overview
4.41.3 Mechanism of Action
4.41.4 Current Status
4.42 BMP9 Drug Details
4.42.1 Snapshot
4.42.2 Drug Overview
4.42.3 Mechanism of Action
4.42.4 Current Status
4.42.5 Trial details
4.43 GMA302 Drug Details
4.43.1 Snapshot
4.43.2 Drug Overview
4.43.3 Mechanism of Action
4.43.4 Current Status
4.43.5 Trial Details
4.44 INV-240 Drug Details
4.44.1 Snapshot
4.44.2 Drug Overview
4.44.3 Mechanism of Action
4.44.4 Current Status
4.45 KAR5585 Drug Details
4.45.1 Snapshot
4.45.2 Drug Overview
4.45.3 Mechanism of Action
4.45.4 Current Status
4.45.5 Trial Details
4.46 MFC1040 Drug Details
4.46.1 Snapshot
4.46.2 Drug Overview
4.46.3 Mechanism of Action
4.46.4 Current Status
4.46.5 Trial Details
4.47 MFC2040 Drug Details
4.47.1 Snapshot
4.47.2 Drug Overview
4.47.3 Mechanism of Action
4.47.4 Current Status
4.48 R197 Drug Details
4.48.1 Snapshot
4.48.2 Drug Overview
4.48.3 Mechanism of Action
4.48.4 Current Status
4.49 ABI-009 Drug Details
4.49.1 Snapshot
4.49.2 Drug Overview
4.49.3 Mechanism of Action
4.49.4 Current Status
4.50 SPI-054 Drug Details
4.50.1 Snapshot
4.50.2 Drug Overview
4.50.3 Mechanism of Action
4.50.4 Current Status
4.50.5 Trial Details
4.51 Tacrolimus Drug Details
4.51.1 Snapshot
4.51.2 Drug Overview
4.51.3 Mechanism of Action
4.51.4 Current Status
4.51.5 Trial Details
4.52 Tiprelestat Drug Details
4.52.1 Snapshot
4.52.2 Drug Overview
4.52.3 Mechanism of Action
4.52.4 Current Status
4.52.5 Trial Details
4.53 TR-422 Drug Details
4.53.1 Snapshot
4.53.2 Drug Overview
4.53.3 Mechanism of Action
4.53.4 Current Status

5 Recent Developments in Pulmonary Arterial Hypertension pipeline
5.1 Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension- November 2017
5.2 Ralinepag Shows Promise in Treating PAH - October 2017
5.3 Capricor Announces Seven New Patent Applications from Cedars-Sinai Medical Center- January 2018
5.4 FDA Agrees for Resubmission of Trevyent NDA Application- December 2017
5.5 Corsair Pharma and United Therapeutics Form Strategic Partnership- January 2018

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Pulmonary Arterial Hypertension pipeline by Phase, H1- 2018
Figure 2: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018
Figure 3: Company wise pipeline Drug Phases, H1- 2018
Figure 4: Pulmonary Arterial Hypertension pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise pipeline Drug Phases, H1- 2018

1.2 List of Tables
Table 1: Pulmonary Arterial Hypertension pipeline by Phase, H1- 2018
Table 2: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018 (1)
Table 3: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018 (2)
Table 4: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018 (3)
Table 5: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018 (4)
Table 6: Pulmonary Arterial Hypertension pipeline by Companies, H1- 2018 (5)
Table 7: Pulmonary Arterial Hypertension pipeline by Mechanism of Action, H1- 2018
Table 8: Aadi Bioscience, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 9: Acceleron Pharma Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 10: Actelion Pharmaceuticals- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 11: Aerogen Pharma Limited- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 12: APT Therapeutics, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 13: Arena Pharmaceuticals Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 14: Asklepion Pharmaceuticals, LLC- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 15: AVEO Pharmaceuticals Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 16: Bial-Portela & Ca. S.A- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 17: Biogen, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 18: Bristol-Myers Squibb Co- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 19: Camurus AB- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 20: Capricor Therapeutics, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 21: Celsion Corp- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 22: Celtaxsys, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 23: Chugai Pharmaceutical Co Ltd- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 24: Complexa Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 25: Corsair Pharma, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 26: Galectin Therapeutics Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 27: GlaxoSmithKline Pharmaceuticals Ltd- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 28: Gmax Biopharm Biomedical Engineering Co., Ltd.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 29: Insmed, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 30: Invent Pharmaceuticals, Inc. - Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 31: Karos Pharmaceuticals, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 32: Liquidia Technologies Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 33: LTT Bio-Pharma Co., Ltd.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 34: Lung Biotechnology PBC- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 35: MannKind Corp- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 36: MaxCyte, Inc.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 37: Mezzion Pharma Co Ltd- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 38: Mifcare.ca- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 39: MORPHOGEN-IX Limited- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 40: Novartis International AG- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 41: Peloton Therapeutics Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 42: PhaseBio Pharmaceuticals, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 43: Proteo Biotech AG- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 44: Pulmokine, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 45: Radikal Therapeutics Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 46: Reata Pharmaceuticals Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 47: Respira Therapeutics, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 48: Reviva Pharmaceuticals, Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 49: Savara Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 50: Selten Pharma, LLC.- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 51: Serodus ASA- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 52: SteadyMed Therapeutics Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 53: Suda Ltd- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 54: Tritech Biopharmaceuticals Co Ltd- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 55: Vicore Pharma AB- Pulmonary Arterial Hypertension pipeline, H1- 2018
Table 56: Vivus Inc- Pulmonary Arterial Hypertension pipeline, H1- 2018

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aadi Bioscience, Inc.
  • Biogen, Inc.
  • Galectin Therapeutics Inc
  • Lung Biotechnology PBC
  • Novartis International AG
  • Savara Inc
  • MORE
  • Pulmonary Arterial Hypertension pipeline comprises of 53 drugs under development as of March 2018. Of these, 15 drugs are in Phase 1 and 9 drugs in phase 2, 5 drugs in Phase 3. Further, 19 drugs are in Pre-clinical stage and 4 drugs in research phase. One drug is in pre-registration stage.
  • 60 companies are developing the pipeline for Pulmonary Arterial Hypertension. Of this, MORPHOGEN-IX Limited, Mifcare.ca, Galectin Therapeutics Inc, and GlaxoSmithKline Pharmaceuticals Ltd have highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is prostacyclin analogue.
  • Nine compounds have been awarded orphan drug status for PAH.
Note: Product cover images may vary from those shown
5 of 6
  • APT Therapeutics, Inc.
  • AVEO Pharmaceuticals Inc.
  • Aadi Bioscience, Inc.
  • Acceleron Pharma Inc
  • Actelion Pharmaceuticals
  • Aerogen Pharma Limited
  • Arena Pharmaceuticals Inc.
  • Asklepion Pharmaceuticals, LLC
  • Bial-Portela & Ca. S.A
  • Biogen, Inc.
  • Bristol-Myers Squibb Co
  • Camurus AB
  • Capricor Therapeutics, Inc
  • Celsion Corp
  • Celtaxsys, Inc.
  • Chugai Pharmaceutical Co Ltd
  • Complexa Inc
  • Corsair Pharma, Inc.
  • Galectin Therapeutics Inc
  • GenThera
  • GlaxoSmithKline Pharmaceuticals Ltd
  • Gmax Biopharm Biomedical Engineering Co., Ltd.
  • Insmed, Inc.
  • Invent Pharmaceuticals, Inc.
  • Japan Tobacco Inc
  • Johnson & Johnson
  • Karos Pharmaceuticals, Inc
  • LTT Bio-Pharma Co., Ltd.
  • Liquidia Technologies Inc
  • Lung Biotechnology PBC
  • MannKind Corp
  • MaxCyte, Inc.
  • Mezzion Pharma Co Ltd
  • Mifcare.ca
  • Nippon Shinyaku
  • Nissan Chemical Industries
  • Novartis AG
  • Novartis International AG
  • Peloton Therapeutics Inc
  • PhaseBio Pharmaceuticals, Inc
  • Proteo Biotech AG
  • Pulmokine, Inc
  • Radikal Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Respira Therapeutics, Inc
  • Reviva Pharmaceuticals, Inc
  • Savara Inc
  • Selten Pharma, LLC.
  • Serodus ASA
  • SteadyMed Therapeutics Inc
  • Suda Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tritech Biopharmaceuticals Co Ltd
  • United Therapeutics Corp
  • Vicore Pharma AB
  • Vivus Inc
  • toray
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll